Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (281-290 of 384) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M Devine, Kouros Owzar, William Blum, et al.
Leukemia|January 8, 2021
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Leukemia|June 10, 2021
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
The New England Journal of Medicine|May 3, 2008
MicroRNA expression in cytogenetically normal acute myeloid leukemiaGuido Marcucci, Michael D Radmacher, Kati Maharry, et al.
Blood|December 15, 2025
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST TrialJorge E Cortes, Timothy P Hughes, Jianxiang Wang, et al.
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemiaRainer Claus, David M Lucas, Stephan Stilgenbauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Haematologica|June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Kati Maharry, Michael D Radmacher, et al.
Pageof 39

Showing results (281-290 of 384) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M Devine, Kouros Owzar, William Blum, et al.
Leukemia|January 8, 2021
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
Leukemia|June 10, 2021
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisHagop M Kantarjian, Timothy P Hughes, Richard A Larson, et al.
The New England Journal of Medicine|May 3, 2008
MicroRNA expression in cytogenetically normal acute myeloid leukemiaGuido Marcucci, Michael D Radmacher, Kati Maharry, et al.
Blood|December 15, 2025
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST TrialJorge E Cortes, Timothy P Hughes, Jianxiang Wang, et al.
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
Blood|January 26, 2022
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trialAlexander E Perl, Richard A Larson, Nikolai A Podoltsev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemiaRainer Claus, David M Lucas, Stephan Stilgenbauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Haematologica|June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Kati Maharry, Michael D Radmacher, et al.
Pageof 39